PoisoningNCT06798129
Effects of Extracorporeal Treatment in Patients With Acute Poisoning
An observational study of Poisoning and Extracorporeal Treatment, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School at 1 site in China.
Trial summary
This study aims to estimate the effect of extracorporeal treatments (ECTRs) on 28-day survival in patients with acute poisoning. The treatment strategy was receipt of ECTR (hemoperfusion, hemodialysis, continuous kidney replacement therapy, and/or or plasma exchange) versus a non-ECTR strategy. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Poisoning, Extracorporeal Treatment
- What is being tested?
- Extracorporeal Treatment
- Type of treatment
- Surgery or procedure
- How many people
- 5,269 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2015to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients with acute poisoning
Who may be able to join
- 12 years of age and older
- History of acute poisoning
Who cannot join
- missing records in survival outcome
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Extracorporeal Treatment in Patients With Acute Poisoning in Jiangsu Province, China: A Multi-center Target Trial Emulation
This study aims to estimate the effect of extracorporeal treatments (ECTRs) on 28-day survival in patients with acute poisoning. The treatment strategy was receipt of ECTR (hemoperfusion, hemodialysis, continuous kidney replacement therapy, and/or or plasma exchange) versus a non-ECTR strategy.
- Conditions
- Poisoning, Extracorporeal Treatment
- Being tested
- Extracorporeal Treatment
- Medical subject headings
- Poisoning
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extracorporeal TreatmentProcedure or surgery
Extracorporeal treatments include hemoperfusion, hemodialysis, continuous kidney replacement therapy, and plasma exchange.
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival outcome
Measured: 28 days within the index date of presentation at emergency department
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2025
- Study start1 Jan 2015
- Primary completion31 Dec 2023
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PoisoningStudies of the same condition, open and under way.
- More trials run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 5,269 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hao Sun, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06798129
- Sponsor's protocol ID
- 2025-1054-01-01
- Status last verified
- Nov 2025
- First submitted
- 23 Jan 2025
- Last updated
- 5 Dec 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Extracorporeal Treatment in Patients With Acute Poisoning in Jiangsu Province, China: A Multi-center Target Trial Emulation
- ClinicalTrials.gov ID
- NCT06798129
- Acronym / sponsor ID
- 2025-1054-01-01
- Conditions
- Poisoning, Extracorporeal Treatment
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,269 participants (actual)
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolUniversity, hospital or other
- Study start
- 1 Jan 2015 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 29 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to estimate the effect of extracorporeal treatments (ECTRs) on 28-day survival in patients with acute poisoning. The treatment strategy was receipt of ECTR (hemoperfusion, hemodialysis, continuous kidney replacement therapy, and/or or plasma exchange) versus a non-ECTR strategy.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients with acute poisoning
Key inclusion criteria (2 listed)
- 12 years of age and older
- History of acute poisoning
Key exclusion criteria (1 listed)
- missing records in survival outcome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extracorporeal TreatmentExtracorporeal treatments include hemoperfusion, hemodialysis, continuous kidney replacement therapy, and plasma exchange. | Procedure or surgery | – |
Primary outcome
Survival outcome
Time frame: 28 days within the index date of presentation at emergency department
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2025.
Related trials for Poisoning
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
Recruiting
Evaluating the Impacts of Informal Tick and Tickborne Disease Educational Tools on Children
Tick Bites
RecruitingObservational study
Predictive Factors for Occlusal Changes in Obstructive Sleep Apnea Treatment With Mandibular Advancement Appliance
Obstructive Sleep Apnea Syndrome
Active, not recruitingPhase 1
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Small Cell Lung Carcinoma
RecruitingPhase 3
Assessment of The Potential Therapeutic Effects of Trimetazidine on Aluminium Phosphide-Induced Cardiotoxicity as an Adjuvant Therapy: A Pilot Study
Aluminum Phosphide Poisoning
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Poisoning and Extracorporeal Treatment, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival outcome (time frame: 28 days within the index date of presentation at emergency department). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2025.